← All trials
NCT07095465
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 31, 2025
- Primary completion
- Feb 28, 2029
- Completion date
- Mar 31, 2029
- First posted
- Jul 31, 2025
- Last posted
- Jul 31, 2025
- Enrollment
- 126
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Acadia PharmaceuticalsLead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.